Maximizing the value of genomics in the drug discovery and development process.
Genomics and all the associated technologies it has spawned have fundamentally changed the way research and development organizations carry out the work they do in the early stages of discovery. However, successful organizations must move from product concept through to registration as efficiently as possible. In order to achieve this, the early "basic" science must be combined with the clinical perspective from the start. Furthermore, since the genomics industry was first established in the early 1990s it has evolved from tool and data suppliers to drug development companies. It is therefore likely that we will see technology advances in genomics become more limited in the years ahead.
Spence
Paul
P
Maxygen, 200 Penobscot Drive, Redwood City, CA 94063, USA. paul.spence@maxygen.com
D018076:DNA, Complementary / Q000235:genetics; D015195:Drug Design; D004345:Drug Industry / Q000191:economics; D023281:Genomics / Q000191:economics / Q000639:trends*; D010600:Pharmacology / Q000191:economics / Q000639:trends*
D018076:DNA, Complementary